CL2011000244A1 - Formulacion farmaceutica intra-arterial que comprende particulas esfericas que contienen un factor de crecimiento y un excipiente biodegradable, en donde el diametro medio de dichas particulas es de 15-20 micrometros, con una desviacion estandar de (+/-) 1 micrometro en al menos 99% de las particulas; y su uso en el tratamiento de infarto al miocardio, trastorno cardiaco isquemico, entre otros. - Google Patents

Formulacion farmaceutica intra-arterial que comprende particulas esfericas que contienen un factor de crecimiento y un excipiente biodegradable, en donde el diametro medio de dichas particulas es de 15-20 micrometros, con una desviacion estandar de (+/-) 1 micrometro en al menos 99% de las particulas; y su uso en el tratamiento de infarto al miocardio, trastorno cardiaco isquemico, entre otros.

Info

Publication number
CL2011000244A1
CL2011000244A1 CL2011000244A CL2011000244A CL2011000244A1 CL 2011000244 A1 CL2011000244 A1 CL 2011000244A1 CL 2011000244 A CL2011000244 A CL 2011000244A CL 2011000244 A CL2011000244 A CL 2011000244A CL 2011000244 A1 CL2011000244 A1 CL 2011000244A1
Authority
CL
Chile
Prior art keywords
particles
treatment
pharmaceutical formulation
myocardial infarction
arterial
Prior art date
Application number
CL2011000244A
Other languages
English (en)
Spanish (es)
Inventor
Ginard Bernardo Nadal
Original Assignee
Coretherapix Slu Es/Es
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39846672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011000244(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coretherapix Slu Es/Es filed Critical Coretherapix Slu Es/Es
Publication of CL2011000244A1 publication Critical patent/CL2011000244A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2011000244A 2008-08-05 2011-02-04 Formulacion farmaceutica intra-arterial que comprende particulas esfericas que contienen un factor de crecimiento y un excipiente biodegradable, en donde el diametro medio de dichas particulas es de 15-20 micrometros, con una desviacion estandar de (+/-) 1 micrometro en al menos 99% de las particulas; y su uso en el tratamiento de infarto al miocardio, trastorno cardiaco isquemico, entre otros. CL2011000244A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0814302.6A GB0814302D0 (en) 2008-08-05 2008-08-05 Compounds and methods

Publications (1)

Publication Number Publication Date
CL2011000244A1 true CL2011000244A1 (es) 2011-07-15

Family

ID=39846672

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000244A CL2011000244A1 (es) 2008-08-05 2011-02-04 Formulacion farmaceutica intra-arterial que comprende particulas esfericas que contienen un factor de crecimiento y un excipiente biodegradable, en donde el diametro medio de dichas particulas es de 15-20 micrometros, con una desviacion estandar de (+/-) 1 micrometro en al menos 99% de las particulas; y su uso en el tratamiento de infarto al miocardio, trastorno cardiaco isquemico, entre otros.

Country Status (13)

Country Link
US (3) US20120195939A1 (cg-RX-API-DMAC7.html)
EP (1) EP2323626B1 (cg-RX-API-DMAC7.html)
JP (1) JP5623400B2 (cg-RX-API-DMAC7.html)
KR (1) KR101639827B1 (cg-RX-API-DMAC7.html)
CN (1) CN102170868A (cg-RX-API-DMAC7.html)
AU (1) AU2009279086B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0917571B1 (cg-RX-API-DMAC7.html)
CA (1) CA2732785C (cg-RX-API-DMAC7.html)
CL (1) CL2011000244A1 (cg-RX-API-DMAC7.html)
ES (1) ES2677005T3 (cg-RX-API-DMAC7.html)
GB (1) GB0814302D0 (cg-RX-API-DMAC7.html)
MX (1) MX2011001261A (cg-RX-API-DMAC7.html)
WO (1) WO2010015665A2 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
GB0814302D0 (en) 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
US10195252B2 (en) 2012-08-03 2019-02-05 University of Pittsburgh—of the Commonwealth System of Higher Education Recruitment of mensenchymal cells using controlled release systems
EP3563859B1 (en) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
EP2914273B1 (en) * 2012-10-26 2018-07-04 Cedars-Sinai Medical Center Therapeutic cells depleted of specific subpopulations of cells for use in tissue repair of regeneration
EP2948543A1 (en) * 2013-01-24 2015-12-02 Bernardo Nadal-Ginard Modulation of cardiac stem-progenitor cell differentiation, assays and uses thereof
ES2606636T3 (es) * 2013-01-24 2017-03-24 Pierre Fabre Médicament S.A.S. Composición que comprende un antagomir encapsulado
EP4494699A3 (en) 2014-10-03 2025-04-30 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
CN104650333B (zh) * 2015-02-05 2016-08-24 浙江大学 聚乳酸/氢化聚丁二烯热塑性超分子弹性体及其制备方法
PL3264997T3 (pl) 2015-03-02 2019-07-31 Accurate Medical Therapeutics Ltd. Cewniki z otworami bocznymi do modyfikowania i podawania zawiesin pacjentowi
US10010400B2 (en) 2015-03-30 2018-07-03 Taris Biomedical Llc Devices and methods for local delivery of drug to upper urinary tract
WO2017123662A1 (en) 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
JP6921116B2 (ja) 2016-05-04 2021-08-18 アキュレイト メディカル セラピューティクス リミテッド スリットパターンを有する塞栓マイクロカテーテルヘッド
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
WO2017220615A1 (en) 2016-06-20 2017-12-28 Virbac Method and apparatus for preparing a micro-particles composition
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
JP7336769B2 (ja) 2017-04-19 2023-09-01 シーダーズ―シナイ メディカル センター 骨格筋ジストロフィーを治療する方法及び組成物
JP7364193B2 (ja) 2017-11-02 2023-10-18 アキュレイト メディカル セラピューティクス リミテッド 内蔵フィルタを有する塞栓術用カテーテル
WO2019126068A1 (en) 2017-12-20 2019-06-27 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
CN112203690A (zh) * 2018-01-12 2021-01-08 哈佛大学校长及研究员协会 与具有粘附颗粒的巨噬细胞和/或单核细胞有关的组合物和方法
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
WO2020234889A1 (en) 2019-05-23 2020-11-26 Accurate Medical Therapeutics Ltd. Embolization catheter for reflux free delivery of microspheres
US20240082167A1 (en) * 2021-01-22 2024-03-14 University Of Connecticut Synthetic artificial stem cells (sasc)
CN121099998A (zh) * 2023-02-02 2025-12-09 银溪制药股份有限公司 使用igf-1嵌合蛋白的治疗方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
BR9510462A (pt) * 1994-12-16 1998-12-15 Andaris Ltd Micropartículas reticuladas e seu uso como veículos terapéuticos
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
CA2161863A1 (en) 1995-10-31 1997-05-01 Michael Vivian Sefton Angiogenic material and uses thereof
US6511477B2 (en) 1997-03-13 2003-01-28 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
JP2001524096A (ja) * 1997-04-24 2001-11-27 ニコムド イメージング エイエス コントラスト剤を含む不溶性微粒子または小胞を使用する塞栓治療
EP0896825B1 (en) 1997-08-14 2002-07-17 Sulzer Innotec Ag Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors
AU1384199A (en) 1997-11-07 1999-05-31 Chiron Corporation Method for producing igf-1 sustained-release formulations
JP2002527401A (ja) 1998-10-13 2002-08-27 カイロン コーポレイション Ｆｇｆの脈管形成的に有効な単位用量および投与方法
CN1200693C (zh) 1998-11-18 2005-05-11 佛罗里达大学 制备包衣药粒及药物制剂的方法
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
US7547674B2 (en) 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
JPWO2003059375A1 (ja) * 2002-01-17 2005-05-19 株式会社カルディオ 組織再生複合療法
US20030199464A1 (en) 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
AU2003272284B2 (en) * 2002-09-05 2009-03-05 Catherine G. Ambrose Antibiotic microspheres for treatment of infections and osteomyelitis
US20070122487A1 (en) * 2003-03-19 2007-05-31 University Of Kentucky Research Foundation (Poly(acryloyl-hydroxyethyl starch)-plga composition microspheres
ES2600554T3 (es) * 2003-07-18 2017-02-09 Oakwood Laboratories L.L.C. Prevención de la reducción del peso molecular del polímero, de la formación de impurezas y de la gelificación en composiciones poliméricas
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
JP4532092B2 (ja) * 2003-09-30 2010-08-25 泰彦 田畑 血管新生剤
US20070116768A1 (en) 2003-12-09 2007-05-24 Michael Chorny Sustained release preparations composed of biocompatible complex microparticles
JP5048323B2 (ja) * 2004-03-31 2012-10-17 株式会社ツーセル 損傷組織の治療剤と治療方法
US7854944B2 (en) 2004-12-17 2010-12-21 Advanced Cardiovascular Systems, Inc. Tissue regeneration
ES2273572B1 (es) * 2005-05-04 2008-04-01 Universidad De Sevilla Procedimiento de preparacion de particulas de tamaño micro y nanometrico con productos labiles y particulas obtenidas.
WO2007028053A2 (en) 2005-09-02 2007-03-08 X-Cell Medical Incorporated Methods of treating and preventing cardiac disorders
KR100718329B1 (ko) 2005-09-08 2007-05-14 광주과학기술원 다당류로 기능화된 수화젤막을 가지는 나노입자와 이를포함하는 서방형 약물전달시스템 및 그 제조방법
WO2007055561A1 (en) * 2005-11-11 2007-05-18 Vascular Biosciences R-ras activity in vascular regulation
CN101563097A (zh) * 2005-11-14 2009-10-21 企业合伙人风险资本公司 用于组织损伤的干细胞生长因子疗法
CU23388B6 (es) 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
PL2087890T3 (pl) 2006-10-19 2014-08-29 Ono Pharmaceutical Co Preparat o przedłużonym uwalnianiu do terapii regeneracyjnej tkanki
WO2008108736A1 (en) 2007-03-06 2008-09-12 Agency For Science, Technology And Research Particles for delivery of bioactive factors
US20110059172A1 (en) 2008-01-29 2011-03-10 Arthur Tzianabos Therapeutic compositions
US8642333B2 (en) 2008-02-04 2014-02-04 Massachusetts Institute Of Technology Particulate delivery vehicles for embryoid bodies
US20090297621A1 (en) * 2008-06-03 2009-12-03 Abbott Cardiovascular Systems Inc. Microparticles For The Treatment Of Disease
GB0814302D0 (en) 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods

Also Published As

Publication number Publication date
KR101639827B1 (ko) 2016-07-14
CN102170868A (zh) 2011-08-31
US8846099B2 (en) 2014-09-30
AU2009279086B2 (en) 2014-05-22
CA2732785C (en) 2016-11-22
US20130315997A1 (en) 2013-11-28
US20130189321A1 (en) 2013-07-25
KR20110051212A (ko) 2011-05-17
GB0814302D0 (en) 2008-10-01
EP2323626A2 (en) 2011-05-25
JP2011529946A (ja) 2011-12-15
WO2010015665A2 (en) 2010-02-11
AU2009279086A1 (en) 2010-02-11
MX2011001261A (es) 2011-08-08
EP2323626B1 (en) 2018-04-11
JP5623400B2 (ja) 2014-11-12
CA2732785A1 (en) 2010-02-11
BRPI0917571A2 (pt) 2020-08-11
WO2010015665A3 (en) 2010-10-07
ES2677005T3 (es) 2018-07-27
BRPI0917571B1 (pt) 2022-01-04
US20120195939A1 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
CL2011000244A1 (es) Formulacion farmaceutica intra-arterial que comprende particulas esfericas que contienen un factor de crecimiento y un excipiente biodegradable, en donde el diametro medio de dichas particulas es de 15-20 micrometros, con una desviacion estandar de (+/-) 1 micrometro en al menos 99% de las particulas; y su uso en el tratamiento de infarto al miocardio, trastorno cardiaco isquemico, entre otros.
Heuschkel et al. Microemulsions—modern colloidal carrier for dermal and transdermal drug delivery
Dembitsky Bioactive peroxides as potential therapeutic agents
MX2019009271A (es) Portador de sustancia fisiologicamente activa.
MX2019003467A (es) Formulaciones y metodos para la administracion vaginal de antiprogestinas.
CO2018011051A2 (es) Formas de dosificación de liberación modificada disuasivas de abuso
ES2721898T3 (es) Formulaciones estables para liofilizar partículas terapéuticas
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
BR112015018087A8 (pt) composto, composição farmacêutica e uso
AR082579A2 (es) Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidad
PE20080210A1 (es) Suspensiones acuosas de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]-amino]-2-pirimidinil]-amino]-benzonitrilo (tmc278)
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
CO2020000328A2 (es) Formulaciones a largo plazo
BR112015018095A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
CL2009001077A1 (es) Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo.
MX2015012783A (es) Administracion subcutanea de una desintegrina y metaloproteinasa con motivos tipo i de trombospondina 13 (adamts13).
CL2008002747A1 (es) Compuestos derivados de furo y tienopirimidina; composicion farmaceutica; metodo para modular la actividad del receptor de histamina h4; y uso en el tratamiento de trastornos tales como inflamacion, trastornos alergicos, dermatologicos, entre otros.
CO7151496A2 (es) Agentes terapeúticos para administración subcutánea optimizados
BR112014009242A2 (pt) nanossuspensão farmacêutica
MX2023000439A (es) Formulaciones a largo plazo.
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
CO2022003583A2 (es) Compuestos de curcumina y aminoácidos básicos
CL2009000330A1 (es) Composicion farmaceutica que comprende microcapsulas de sabor enmascarado con un nucleo de ranitidina y al menos dos recubrimientos sobre el; tabla de rapida desintegracion oral; metodo para preparar la composicion farmaceutica; metodo para preparar la tableta, util para tratar o prevenir trastornos gastrointestinales.
MY159739A (en) Freeze-dried preparation of tetrodotoxin and the producing method thereof
CL2011001207A1 (es) Extruidos que contienen al menos una sustancia farmacéuticamente activa en forma de agujas, tal que la relación entre el tamaño de partículas de la sustancia farmacéuticamente activa con forma de agujas y el diámetro de la cadena es de al menos 1:20; composición farmacéutica; y su uso para preparar medicamentos.